tiprankstipranks

Xvivo Perfusion downgraded to Sell from Buy at Danske Bank

Danske Bank downgraded Xvivo Perfusion (XVIPF) to Sell from Buy with a price target of SEK 325, down from SEK 560. The firm sees short-term headwinds and a “too rich” valuation.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1